# Vittoria Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vittoria-biotherapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.vittoriabio.com/
- Total disclosed funding: $18M
- Latest round: Seed (Nov 14, 2023)
- Investors on record: 7

## About

Founded in 2021 and based in Pennsylvania, US, Vittoria Biotherapeutics, Inc. operates as a Biotechnology research company that provides technologies related to cell therapies and gene editing. The company was co-founded by Nicholas Siciliano(CEO) and Bruce Peacock. In June 2022, the firm raised USD 10 million in Seed funding from investors Agent Capital and Tellus BioVentures.

The company offers Senza5 which is a cell therapy engineering and manufacturing platform, that combines the power of genetic engineering and a proprietary five-day manufacturing process. The firm primary offering is the development of gene editing and cell therapies, with a focus on T cell engineering and CAR T cell therapies.

## Funding rounds

- Seed, Nov 14, 2023, $9.3M — University of Pennsylvania Endowment, Valley Forge Private Equity, New York Blood Center, BioAdvance, The Leukemia & Lymphoma Society, Agent Capital, Tellus BioVentures
- Seed, Jul 23, 2021, $8.7M — University of Pennsylvania Endowment, Agent Capital, Tellus BioVentures

## Investors

- University of Pennsylvania Endowment — Seed
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Seed
- Tellus BioVentures (https://capitalatlas.ai/funds/tellus-bioventures) — Seed
- Valley Forge Private Equity (https://capitalatlas.ai/funds/valley-forge-private-equity) — Seed
- New York Blood Center — Seed
- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed
- The Leukemia & Lymphoma Society — Seed